- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Corporate and Securities Litigation
- E-Discovery
- Global Construction and Infrastructure Disputes
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
David J. Farber
Insights 20 results
Client Alert
November 19, 2025
2026 Physician Fee Schedule Final Rule Changes to ASP Calculation and Reporting Policies and Other Drug Payment Policies
Client Alert
June 5, 2025
Administrative, Congressional, and State Interest Signal a Potential Breakthrough Moment for Psychedelics
Article · Source: Law360
September 17, 2024
CMS' New 'Breakthrough' Device Policy Shows Little Promise
Client Alert
September 4, 2024
Transitional Coverage for Emerging Technologies: CMS’s Latest, But Not Necessarily Greatest, Coverage with Evidence Approach
Client Alert
Client Alert
October 3, 2023
FDA's Latest Salvo in the LDT Wars
Client Alert
July 12, 2023
A Pathway for Medicare Coverage for Breakthrough Devices: Take Two
Article · Source: Alliance for Aging Research
February 13, 2023
Facade of Evidence: How Medicare's Coverage with Evidence Development Paradigm Rations Care and Exacerbates Inequity
COVID-19 Vaccine Updates
April 30, 2021
CDC Reveals New Guidelines for Fully Vaccinated Individuals
COVID-19 Vaccine Updates
April 30, 2021
CDC Says Pfizer and Moderna COVID-19 Vaccines are 94% Effective Against Hospitalization in Older Adults
COVID-19 Vaccine Updates
April 16, 2021
CDC and FDA Release Joint Statement on Johnson & Johnson COVID-19 Vaccine
COVID-19 Vaccine Updates
April 16, 2021
HHS Office for Civil Rights Publishes Legal Guidance Around Access to COVID-19 Vaccines for People with Disabilities and Older Adults